Jump to main content
Jump to site search

Issue 4, 2019, Issue in Progress
Previous Article Next Article

DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

Author affiliations

Abstract

Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron–affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

Graphical abstract: DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

Back to tab navigation

Supplementary files

Article information


Submitted
22 Oct 2018
Accepted
06 Jan 2019
First published
15 Jan 2019

This article is Open Access

RSC Adv., 2019,9, 1982-1989
Article type
Paper

DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

C. Zhang, H. Zhang, M. Han, X. Yang, C. Pei, Z. Xu, J. Du, W. Li and S. Chen, RSC Adv., 2019, 9, 1982
DOI: 10.1039/C8RA08735K

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

Reproduced material should be attributed as follows:

  • For reproduction of material from NJC:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
  • For reproduction of material from PCCP:
    [Original citation] - Published by the PCCP Owner Societies.
  • For reproduction of material from PPS:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
  • For reproduction of material from all other RSC journals:
    [Original citation] - Published by The Royal Society of Chemistry.

Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.


Social activity

Search articles by author

Spotlight

Advertisements